Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sorafenib maintenance after allo-SCT in FLT3-ITD+ AML
DRKS00000591Phase 2Completed
- Sponsor
- Philipps-Universität Marburg
- Start
- Oct 2010
- Modality
- Small Molecules
- Countries
- 2
01
Overview
A Phase 2 trial of sorafenib in acute myeloid leukemia (AML), sponsored by Philipps-Universität Marburg. Started Oct 2010; status: completed.
02
Drugs
sorafenib
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on DRKS00000591.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on DRKS00000591.